Induction of protective CD4+ T cell-mediated immunity by a Leishmania peptide delivered in recombinant influenza viruses

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Kedzierska, Katherine ^a   Curtis, Joan M ^a,b   Valkenburg, Sophie A ^a   Hatton, Lauren A ^a   Kiu, Hiu ^a,b   Doherty, Peter C ^a,c   Kedzierski, Lukasz ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INFLUENZA VACCINE; INFLUENZA VIRUS VECTOR; INTERLEUKIN 12; LEISHMANIA SPECIFIC LACK 158-173 CD4+ T CELL PEPTIDE; LEISHMANIA VACCINE; PROTOZOAL PROTEIN; SIALIDASE; UNCLASSIFIED DRUG; VIRUS VECTOR; DNA VACCINE; LACK ANTIGEN, LEISHMANIA; LYSOZYME; PARASITE ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; GENETIC ENGINEERING; IMMUNOGENICITY; IN VIVO STUDY; INFLUENZA VIRUS A; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; LEISHMANIA; LEISHMANIASIS; MOUSE; NONHUMAN; PARASITE LOAD; REVERSE GENETICS; SPLEEN; TH1 CELL; VACCINATION; VIRUS RECOMBINANT; VIRUS STRAIN; ANIMAL; CHEMISTRY; GENE VECTOR; GENETICS; IMMUNOLOGY; METABOLISM;

INFLUENZA A VIRUS; LEISHMANIA MAJOR; MUS; ORTHOMYXOVIRIDAE;

ANIMALS; ANTIGENS, PROTOZOAN; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; GENETIC VECTORS; IMMUNITY, CELLULAR; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INTERFERON-GAMMA; LEISHMANIA; LEISHMANIASIS; LEISHMANIASIS VACCINES; MICE; MICE, INBRED BALB C; MURAMIDASE; PROTOZOAN PROTEINS; VACCINATION; VACCINES, DNA;

EID: 84858633511     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0033161     Document Type: Article

References (63)

1. Handman E, (1999) Cell biology of Leishmania. Adv Parasitol 44: 1-39.
2. Rose K, Curtis J, Baldwin T, Mathis A, Kumar B, et al. (2004) Cutaneous leishmaniasis in red kangaroos: isolation and characterisation of the causative organisms. Int J Parasitol 34: 655-664.
3. Bern C, Maguire JH, Alvar J, (2008) Complexities of assessing the disease burden attributable to leishmaniasis. PLoS Negl Trop Dis 2: e313.
4. World Health Organization (2008) WHO Initiative for Vaccine Research. 23 Available: http://www.who.int/vaccine_research/diseases/soa_parasitic/en/index3.html. Accessed 2012 Feb.
5. Patz JA, Graczyk TK, Geller N, Vittor AY, (2000) Effects of environmental change on emerging parasitic diseases. Int J Parasitol 30: 1395-1405.
6. Kedzierski L, Sakthianandeswaren A, Curtis JM, Andrews PC, Junk PC, et al. (2009) Leishmaniasis: current treatment and prospects for new drugs and vaccines. Curr Med Chem 16: 599-614.
7. de Goede AL, Boers PH, Dekker LJ, Osterhaus AD, Gruters RA, et al. (2009) Characterization of recombinant influenza A virus as a vector for HIV-1 p17 Gag. Vaccine 27: 5735-5739.
8. Stukova MA, Sereinig S, Zabolotnyh NV, Ferko B, Kittel C, et al. (2006) Vaccine potential of influenza vectors expressing Mycobacterium tuberculosis ESAT-6 protein. Tuberculosis (Edinb) 86: 236-246.
9. Miyahira Y, Garcia-Sastre A, Rodriguez D, Rodriguez JR, Murata K, et al. (1998) Recombinant viruses expressing a human malaria antigen can elicit potentially protective immune CD8+ responses in mice. Proc Natl Acad Sci U S A 95: 3954-3959.
10. Zheng H, Palese P, Garcia-Sastre A, (2000) Antitumor properties of influenza virus vectors. Cancer Res 60: 6972-6976.
11. Hoffmann E, Mahmood K, Yang C, Webster R, Greenberg H, et al. (2002) Rescue of influenza B virus from eight plasmids. Proc Natl Acad Sci U S A 99: 11411-11416.
12. La Gruta NL, Kedzierska K, Pang K, Webby R, Davenport MP, et al. (2006) A virus specific CD8+ T cell immunodominance hierarchy determined by antigen dose and percursor frequencies. Proc Natl Acad Sci U S A 103: 994-999.
13. Kedzierska K, Stambas J, Jenkins MR, Keating R, Turner SJ, et al. (2007) Location rather than CD62 L phenotype is critical in the early establishment of influenza-specific CD8+ T cell memory. Proc Natl Acad Sci U S A 104 9782-9787.
14. Sexton A, De Rose R, Reece JC, Alcantara S, Loh L, et al. (2009) Evaluation of recombinant influenza virus-simian immunodeficiency virus vaccines in macaques. J Virol 83: 7619-7628.
15. Joseph T, McAuliffe J, Lu B, Vogel L, Swayne D, et al. (2008) A live attenuated cold-adapted influenza A H7N3 virus vaccine provides protection against homologous and heterologous H7 viruses in mice and ferrets. Virology 378: 123-132.
16. Courret N, Prina E, Mougneau E, Saraiva EM, Sacks DL, et al. (1999) Presentation of the Leishmania antigen LACK by infected macrophages is dependent upon the virulence of the phagocytosed parasites. Eur J Immunol 29: 762-773.
17. Mougneau E, Altare F, Wakil AE, Zheng S, Coppola T, et al. (1995) Expression cloning of a protective Leishmania antigen. Science 268: 563-566.
18. Maasho K, Wolday D, Edjigu M, Soderstrom K, Britton S, et al. (2001) Induction and abrogation of LACK reactive cells in the evolution of human leishmaniasis. Clin Exp Immunol 124: 255-261.
19. Handman E, Hocking RE, Mitchell GF, Spithill TW, (1983) Isolation and characterization of infective and non-infective clones of Leishmania tropica. Mol Biochem Parasitol 7: 111-126.
20. Mitchell GF, Handman E, (1983) Leishmania tropica major in mice: vaccination against cutaneous leishmaniasis in mice of high genetic susceptibility. Aust J Exp Biol Med Sci 61: 11-25.
21. Titus RG, Marchand M, Boon T, Louis JA, (1985) A limiting dilution assay for quantifying Leishmania major in tissues of infected mice. Parasite Immunol 7: 545-555.
22. Kedzierski L, Curtis JM, Doherty PC, Handman E, Kedzierska K, (2008) Decreased IL-10 and IL-13 production and increased CD44 hi T cell recruitment contribute to Leishmania major immunity induced by non-persistent parasites. Eur J Immunol 38: 3090-3100.
23. Kamhawi S, Belkaid Y, Modi G, Rowton E, Sacks D, (2000) Protection against cutaneous leishmaniasis resulting from bites of uninfected sand flies. Science 290: 1351-1354.
24. Coler RN, Goto Y, Bogatzki L, Raman V, Reed SG, (2007) Leish-111f, a recombinant polyprotein vaccine that protects against visceral Leishmaniasis by elicitation of CD4+ T cells. Infect Immun 75: 4648-4654.
25. Townsend AR, McMichael AJ, Carter NP, Huddleston JA, Brownlee GG, (1984) Cytotoxic T cell recognition of the influenza nucleoprotein and hemagglutinin expressed in transfected mouse L cells. Cell 39: 13-25.
26. Wright P, Webster R, (2001) Orthomyxoviruses. In: Knipe D, Howley P, editors. Fields Virology 4th ed. Philadelphia Lippincott Williams and Wilkins pp. 1533-1579.
27. Sun K, Torres L, Metzger DW, (2010) A detrimental effect of interleukin-10 on protective pulmonary humoral immunity during primary influenza A virus infection. J Virol 84: 5007-5014.
28. Scott P, (1989) The role of TH1 and TH2 cells in experimental cutaneous leishmaniasis. Exp Parasitol 68: 369-372.
29. Sacks D, Noben-Trauth N, (2002) The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol 2: 845-858.
30. Julia V, Glaichenhaus N, (1999) CD4(+) T cells which react to the Leishmania major LACK antigen rapidly secrete interleukin-4 and are detrimental to the host in resistant B10.D2 mice. Infection and Immunity 67: 3641-3644.
31. Launois P, Maillard I, Pingel S, Swihart KG, Xenarios I, et al. (1997) IL-4 rapidly produced by V beta 4 V alpha 8 CD4+ T cells instructs Th2 development and susceptibility to Leishmania major in BALB/c mice. Immunity 6: 541-549.
32. Julia V, Rassoulzadegan M, Glaichenhaus N, (1996) Resistance to Leishmania major induced by tolerance to a single antigen. Science 274: 421-423.
33. Gurunathan S, Prussin C, Sacks DL, Seder RA, (1998) Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection. Nature Medicine 4: 1409-1415.
34. Gonzalo RM, Rodriguez JR, Rodriguez D, Gonzalez-Aseguinolaza G, Larraga V, et al. (2001) Protective immune response against cutaneous leishmaniasis by prime/booster immunization regimens with vaccinia virus recombinants expressing Leishmania infantum p36/LACK and IL-12 in combination with purified p36. Microbes and Infection 3: 701-711.
35. Gonzalo RM, del Real G, Rodriguez JR, Rodriguez D, Heljasvaara R, et al. (2002) A heterologous prime-boost regime using DNA and recombinant vaccinia virus expressing the Leishmania infantum P36/LACK antigen protects BALB/c mice from cutaneous leishmaniasis. Vaccine 20: 1226-1231.
36. Melby PC, Yang J, Zhao W, Perez LE, Cheng J, (2001) Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis. Infection and Immunity 69: 4719-4725.
37. Kronenberg K, Brosch S, Butsch F, Tada Y, Shibagaki N, et al. (2010) Vaccination with TAT-antigen fusion protein induces protective, CD8(+) T cell-mediated immunity against Leishmania major. J Invest Dermatol 130: 2602-2610.
38. Ajdary S, Alimohammadian MH, Eslami MB, Kemp K, Kharazmi A, (2000) Comparison of the immune profile of nonhealing cutaneous Leishmaniasis patients with those with active lesions and those who have recovered from infection. Infect Immun 68: 1760-1764.
39. Ajdary S, Riazi-Rad F, Alimohammadian MH, Pakzad SR, (2009) Immune response to Leishmania antigen in anthroponotic cutaneous leishmaniasis. J Infect 59: 139-143.
40. Belkaid Y, Piccirillo CA, Mendez S, Shevach EM, Sacks DL, (2002) CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature 420: 502-507.
41. Belkaid Y, Hoffmann KF, Mendez S, Kamhawi S, Udey MC, et al. (2001) The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure. J Exp Med 194: 1497-1506.
42. Kedzierska K, Venturi V, Valkenburg SA, Davenport MP, Turner SJ, et al. (2008) Homogenization of TCR repertoires within secondary CD62Lhigh and CD62Llow virus-specific CD8+ T cell populations. J Immunol 180: 7938-7947.
43. Christensen JP, Doherty PC, Branum KC, Riberdy JM, (2000) Profound protection against respiratory challenge with a lethal H7N7 influenza A virus by increasing the magnitude of CD8(+) T-cell memory. J Virol 74: 11690-11696.
44. MacLeod MK, McKee A, Crawford F, White J, Kappler J, et al. (2008) CD4 memory T cells divide poorly in response to antigen because of their cytokine profile. Proc Natl Acad Sci U S A 105: 14521-14526.
45. Darrah PA, Patel DT, De Luca PM, Lindsay RW, Davey DF, et al. (2007) Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 13: 843-850.
46. Williams MA, Ravkov EV, Bevan MJ, (2008) Rapid culling of the CD4+ T cell repertoire in the transition from effector to memory. Immunity 28: 533-545.
47. Ravkov EV, Williams MA, (2009) The magnitude of CD4+ T cell recall responses is controlled by the duration of the secondary stimulus. J Immunol 183: 2382-2389.
48. Homann D, Teyton L, Oldstone MB, (2001) Differential regulation of antiviral T-cell immunity results in stable CD8+ but declining CD4+ T-cell memory. Nat Med 7: 913-919.
49. Woodland DL, (2004) Jump-starting the immune system: prime-boosting comes of age. Trends Immunol 25: 98-104.
50. Peters NC, Kimblin N, Secundino N, Kamhawi S, Lawyer P, et al. (2009) Vector transmission of leishmania abrogates vaccine-induced protective immunity. PLoS Pathog 5: e1000484.
51. Kawai T, Akira S, (2007) Antiviral signaling through pattern recognition receptors. J Biochem 141: 137-145.
52. Huber M, Timms E, Mak TW, Rollinghoff M, Lohoff M, (1998) Effective and long-lasting immunity against the parasite Leishmania major in CD8-deficient mice. Infect Immun 66: 3968-3970.
53. Belkaid Y, Von Stebut E, Mendez S, Lira R, Caler E, et al. (2002) CD8+ T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major. J Immunol 168: 3992-4000.
54. Uzonna JE, Joyce KL, Scott P, (2004) Low dose Leishmania major promotes a transient T helper cell type 2 response that is down-regulated by interferon gamma-producing CD8+ T cells. J Exp Med 199: 1559-1566.
55. Bertholet S, Debrabant A, Afrin F, Caler E, Mendez S, et al. (2005) Antigen requirements for efficient priming of CD8+ T cells by Leishmania major-infected dendritic cells. Infect Immun 73: 6620-6628.
56. Bertholet S, Goldszmid R, Morrot A, Debrabant A, Afrin F, et al. (2006) Leishmania antigens are presented to CD8+ T cells by a transporter associated with antigen processing-independent pathway in vitro and in vivo. J Immunol 177: 3525-3533.
57. Houde M, Bertholet S, Gagnon E, Brunet S, Goyette G, et al. (2003) Phagosomes are competent organelles for antigen cross-presentation. Nature 425: 402-406.
58. Rodriguez A, Regnault A, Kleijmeer M, Ricciardi-Castagnoli P, Amigorena S, (1999) Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nat Cell Biol 1: 362-368.
59. Gurunathan S, Stobie L, Prussin C, Sacks DL, Glaichenhaus N, et al. (2000) Requirements for the maintenance of Th1 immunity in vivo following DNA vaccination: a potential immunoregulatory role for CD8+ T cells. J Immunol 165: 915-924.
60. Maassab HF, Bryant ML, (1999) The development of live attenuated cold-adapted influenza virus vaccine for humans. Rev Med Virol 9: 237-244.
61. Mishin VP, Nedyalkova MS, Hayden FG, Gubareva LV, (2005) Protection afforded by intranasal immunization with the neuraminidase-lacking mutant of influenza A virus in a ferret model. Vaccine 23: 2922-2927.
62. Ockenhouse CF, Sun PF, Lanar DE, Wellde BT, Hall BT, et al. (1998) Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. J Infect Dis 177: 1664-1673.
63. Martina BE, van den Doel P, Koraka P, van Amerongen G, Spohn G, et al. (2011) A recombinant influenza A virus expressing domain III of West Nile virus induces protective immune responses against influenza and West Nile virus. PLoS One 6: e18995.